AN infectious disease expert at the University of Port Harcourt Teaching Hospital, Dr Chizaram Onyeaghala, has allayed the fears that Human metapneumovirus (HMPV) is extremely unlikely to be the next ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

COVID-19 accelerates the progression of atherosclerotic plaques, increasing coronary inflammation and the risk of high-risk ...

Yellow fever infections are on the rise in several Americas countries, with the virus expanding its reach outside the zone ...

School closures reduced the impact of COVID-19 in most countries but had negative effects in some, Monash University-led ...

To see how the coronavirus that causes COVID-19, SARS-CoV-2, might affect coronary arteries that supply blood to the heart, ...

New Jersey-based biotechnology company, Grignard Pure LLC, a leader in developing next-generation indoor air treatment solutions for disease mitigation, indoor air quality and pandemic response, is ...

Doctors have found that Covid-19's inflammation can cause long-term cardiovascular issues, such as accelerated plaque buildup ...

As Elon Musk moves to shutter the U.S. Agency for International Development, the agency’s support for the discovery of novel ...